Abstract
Co-trimoxazole (CTX), a combination of sulfamethoxazole (SMZ) and trimethoprim (TMP), is used during pregnancies complicated by infections like Urinary Tract Infections (UTI) and Human Immunodeficiency Virus (HIV), despite potential fetal safety concerns. This study examines CTX’s effects on the placenta using both in vivo and in vitro models. Pregnant mice received CTX for 4 days during both early and late gestation. On gestational day 19, tissues were collected for analysis. Furthermore, in vitro, human BeWo placental cells were exposed to non-cytotoxic concentrations of CTX for 24 h. Gene expression was analyzed by bulk RNA sequencing with pathway analysis, and placental barrier function was assessed by measuring transepithelial electrical resistance (TEER) and fluorescein isothiocyanate-dextran (FITC-D) permeability. In vivo, CTX significantly reduced uterine weight and litter size (p < 0.05), indicating potential reproductive toxicity, which was supported by placental transcriptomic analysis. In vitro, bulk RNA-sequencing of CTX-treated BeWo cells exhibited differential expression of genes related to tight and adherens junctions, indicating impaired placental barrier integrity. This was accompanied by a significant reduction in TEER (p < 0.0001) and an increase in FITC-D permeability (p < 0.001). In addition, CTX activated the ERK1/2 (MAPK3) pathway, as indicated by increased ERK1/2 (p < 0.01) phosphorylation and downregulation of the ERK pathway negative regulators (DUSP genes). Additionally, IL-6 expression levels were reduced in the amniotic fluid (p < 0.01) and placenta of CTX-treated mice, and a similar reduction was observed in CTX-treated BeWo cells at both the transcript (p < 0.05) and protein (p < 0.001) levels. In conclusion, CTX may induce reproductive toxicity and compromise placental barrier integrity, warranting further investigation into its safety during pregnancy.
Graphical Abstract
1 Introduction
Antibiotics are a class of medicines widely prescribed to treat bacterial infectious diseases and have contributed greatly to increased life expectancy (). There is an increase in research into the effects of antibiotic usage during pregnancy. This is an important area of research, as antibiotics comprise 80% of all medicines prescribed during pregnancy, and one in five pregnant individuals will use at least one antibiotic during gestation (; de Jonge et al., 2014). These antibiotics are often prescribed to treat or, in some high-risk populations, to prevent infections, such as urinary tract infections (UTI), respiratory tract infections, or sexually transmitted infections. If left untreated, these infections have detrimental effects on both maternal and fetal health, including spontaneous abortion (). A risk-benefit assessment should be conducted when prescribing antibiotics to pregnant individuals, as antibiotic exposure in pregnancy is linked to several adverse outcomes. Gestational antibiotic exposure is associated with an increased risk of preterm birth (; Nguyen et al., 2022), alterations in infant birth weight () and a higher likelihood of childhood obesity (Mueller et al., 2015).
Co-trimoxazole (CTX), a combination of sulfamethoxazole (SMZ) and trimethoprim (TMP), is used to treat a range of infections during pregnancy, including gestational pneumonia and UTI, and is frequently recommended for HIV-positive pregnant individuals (; ; ; Smilack, 1999; Muanda et al., 2018; MacLean, 2001). The global pooled prevalence of HIV infection among pregnant women is estimated at approximately 2.9%, highlighting the clinical relevance of CTX use during pregnancy (Wu et al., 2023). While CTX use in HIV-positive pregnant women is associated with reduced risk of preterm delivery and neonatal mortality (Walter et al., 2006), first-trimester CTX exposure results in a 2.94-fold increased odds of spontaneous abortion (Muanda et al., 2018). Therefore, its use during pregnancy is recommended only when maternal benefits outweigh potential fetal risks ().
According to the Food and Drug Administration (FDA), CTX carries a category D pregnancy warning (). Despite this, the World Health Organization (WHO) guidelines recommend CTX prophylactic use during all stages of pregnancy in HIV-infected women with a CD4 count ≤350 cells/mm3 (World Health Organization, 2014). Furthermore, UTI represents a major clinical concern during pregnancy and is among the most frequently diagnosed conditions, affecting approximately 23.9% of pregnancies (Salari et al., 2023). For gestational UTI, CTX is considered an effective antibiotic in selected cases throughout pregnancy when administered with folic acid supplementation (; Waltzer, 1981; Matuszkiewicz-Rowińska et al., 2015; ).
CTX works as a bactericidal antibiotic through a two-step blockage of the bacterial folate metabolism, essential in the biosynthesis of nucleic acids and proteins. SMZ inhibits the bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid, while TMP selectively inhibits microbial dihydrofolate reductase, blocking the production of tetrahydrofolic acid from dihydrofolic acid (; Walter et al., 2006; World Health Organization, 2014; Kemnic and Coleman, 2023). Although CTX is more selective for the bacterial reductase enzyme, it could also interfere with human folate metabolism ().
Both SMZ and TMP can cross the placenta (; van Hove et al., 2022; Prokopczyk et al., 1979), and reach the fetal circulation. Their pharmacokinetics in neonates differ from those in adults, with longer half-lives and reduced clearance rate due to immature organ function (Ryan et al., 2013), leading to prolonged exposure, which could pose a risk, as folate is essential in foetal development due to its importance in DNA synthesis. The antifolate abilities of CTX during the first trimester result in an increased risk of congenital malformations, including neural tube, cardiac, and urinary tract defects (Hernández-Díaz et al., 2000; Hernández-Díaz et al., 2001). However, reported rates of congenital abnormalities, low birth weight, spontaneous abortion, and neonatal death vary widely among studies, limiting the overall quality of the evidence (). These potential adverse outcomes may result from disruptions in critical developmental processes during pregnancy, including impaired placental development and function (Thompson et al., 2024; Umapathy et al., 2024), which is pivotal for fetal growth and pregnancy maintenance.
The placenta, as the maternal-fetal interface, forms the sole link between the birthing parent and the fetus during pregnancy. It facilitates maternal-fetal substance exchange, hormone secretion, and barrier protection (). The placental epithelium consists of undifferentiated cytotrophoblasts and differentiated syncytiotrophoblasts, which form the structural and biochemical barrier between the maternal and foetal blood, regulating placental and foetal development (Weiler, 2005). The integrity of the placental epithelial layer is maintained by junctional proteins, including tight junctions (TJs) and adherens junctions (AJs), which regulate the paracellular transport and the permeability of the placental epithelium (; ; ; Tossetta et al., 2014; Marzioni et al., 2001). Any disruption to this junctional network can compromise the integrity of the epithelial layer and potentially affect foetal development (Tossetta et al., 2014). Increased epithelial permeability may enable toxins, pathogens, or other teratogenic compounds to cross the placental barrier; a tighter barrier could hinder the removal of foetal waste products, such as urate (; Uehara et al., 2014).
To maintain this complex and dynamic placental environment, several molecular signaling pathways are involved, among which the mitogen-activated protein kinase (MAPK) pathway is particularly crucial (Nadeau and Charron, 2014). This pathway plays a central role in regulating trophoblast proliferation, differentiation, and survival, as well as mediating the placental response to various physiological and pathological stressors (; ; Zhou et al., 2023).
This study provides novel insights into the effects of CTX on placental barrier integrity and transcriptomic profiles. Despite its use during pregnancies complicated by HIV infection and UTI, the placental effects of CTX remain largely unexplored. To address this knowledge gap, we evaluated reproductive toxicity, CTX-induced changes in placental gene expression, and placental barrier integrity following CTX exposure using complementary in vivo murine pregnancy and in vitro placental barrier models.
2 Materials and methods
2.1 Compounds and reagents
CTX is a combination of SMZ and TMP in a fixed 5:1 ratio. Although administered in this ratio, both compounds behave as independent molecules in vivo, with respective half-lives of 10–13 h and 8–11 h. SMZ and TMP undergo hepatic metabolism and renal excretion as separate entities (; Leegwater et al., 2025). For in vivo administration, CTX, consisting of SMZ and TMP in a 5:1 ratio, was prepared in PBS and administered orally to mice at a dose of 500 mg/kg/day.
For in vitro experiments, SMZ and TMP (Sigma-Aldrich, St. Louis, MO, United States) were dissolved in dimethyl sulfoxide (DMSO 0.1%) (Sigma-Aldrich) to prepare stock solutions of 20 mg/mL. The CTX stock solution was then prepared by mixing SMZ and TMP at a 5:1 ratio and diluted in antibiotic-free cell culture medium. Based on cytotoxicity assays (Figure 2), non-cytotoxic concentrations of SMZ (100 and 200 μg/mL), TMP (5 and 50 μg/mL), and CTX (5 and 50 μg/mL) were selected for subsequent experiments. CTX (50 μg/mL; 5:1 SMZ: TMP ratio) corresponds to ∼41.7 μg/mL SMZ and ∼8.3 μg/mL TMP. The SMZ component approximates human plasma levels (∼57 μg/mL), while TMP exceeds typical plasma levels (∼1.72 μg/mL) (U.S. Food and Drug Administration, 2021) but remains within high-dose therapeutic ranges (). As CTX is the clinically co-prescribed formulation, these conditions reflect the most physiologically relevant exposure in BeWo trophoblast cells. Working dilutions were freshly prepared in antibiotic-free cell culture medium before each experiment. PD98059 (Invitrogen, Frederick, MD, United States) is a selective mitogen-activated protein kinase kinase 1 (MEK1) inhibitor commonly used to block the Extracellular signal-Regulated Kinase 1/2 (ERK1/2) signaling pathway. For ERK pathway inhibition in BeWo cells, PD98059 was applied at a final concentration of 50 µM for 24 h, as previously reported to be effective in cytotrophoblasts (; ).
2.2 Animals
Six-week-old female and nine-week-old male specific pathogen-free (SPF) C3H/HeOuJ mice were purchased from Charles River Laboratories and housed in the animal facility of Utrecht University at controlled temperature (21 °C ± 2 °C) and humidity (50%–55%), with a reversed 12:12 h light/dark cycle (lights on from 7 a.m. till 7 p.m.) with ad libitum access to food and tap water. All experimental procedures were carried out during the light/inactive part of the cycle, and all repeated measurements were performed at the same time block of the day. Animals were kept in individually ventilated cages (IVC) (22 cm × 16 cm×14 cm, floor area 350 cm2, Technilab-BMI, Someren, the Netherlands) and wood-chip bedding (Technilab- BMI), tissues (VWR, the Netherlands), and shelters were available as cage enrichment. The animals were provided standard diets (pelleted food, AIN-93G, Sniff Spezialdiäten, Soest, Germany) and routine care upon arrival at the animal facility, continuing until the end of the experiment. Upon arrival in the animal facility, mice were acclimatized for 1 week, after which the female mice were trained for oral gavage over the course of a week through daily administration of the gavage needle to minimize the gavage-related stress during pregnancy. This study was conducted in accordance with institutional guidelines for the care and use of laboratory animals established by the Animal Ethics Committee of Utrecht University. All animal procedures related to the purpose of the study were approved under license of the national competent authority (CCD), securing full compliance with the European Directive 2010/63/EU for the use of animals for scientific purposes, with the approval number of AVD10800202316818.
2.3 Breeding, pregnancy, and antibiotic exposure
Upon mice’s arrival at the animal facility, male and female mice were housed separately in different cages (2 females/cage and 3 males/cage). After a week of acclimatization, male breeders were housed solitarily for 5 days before being co-housed with their assigned pair of female mice. Forty-eight hours before mating (male-female co-housing), the cages of the male and female mice were exchanged to synchronize the females’ estrus cycles via the Whitten effect. Thereafter, the two female mice were transferred back to their original cage, including the male breeder. Male and female mice were co-housed for 4 days for breeding, with a ratio of one male to 2 females. Twenty-four hours post-breeding was considered as gestational day 0 (GD0). After 4 days of breeding, the breeder male mice were removed from the cages. The bred female mice received CTX via oral gavage at a volume of 400 μL, suspended in PBS (500 mg/kg/day) (; Sivalingam et al., 2008) during two distinct periods of pregnancy (GD1-GD6 and GD13-GD18). The control pregnant mice received 400 µL PBS orally during the mentioned treatment period. On GD19, the pregnant dams were euthanized under deep anesthesia using isoflurane inhalation, followed by decapitation, whereafter samples, including blood, placenta, and amniotic fluid, were isolated for ex vivo analysis.
2.4 Cell culture
The human placenta choriocarcinoma trophoblast BeWo cell line, obtained from the American Type Culture Collection (ATCC-CCL-98, Rockville, MD, United States; passages 42–46), was cultured in cell culture flasks (Corning, Kennebunk, ME, United States) using F-12K medium (Kaighn’s modification of Ham’s F-12 medium; Gibco, Thermo Fisher Scien tific, Paisley, United Kingdom), supplemented with 10% foetal calf serum (Science, Brebières, France), and a 1% mixture of penicillin (100 U/mL) and streptomycin (100 μg/mL). Cells were maintained in a humidified atmosphere of 5% CO2 at 37 °C, and the medium was refreshed three times a week until the cells reached confluence (7 ± 1 days). Confluent cultures were passaged by washing with PBS and detaching the cells using 0.05% trypsin (Gibco, Thermo Fisher Scientific, Wilmington, DE, United States) and 0.54 mM ethylene diamine tetra-acetic acid (EDTA). For exposure to antibiotics, BeWo cells were seeded in either 96 or 24-well plates (CellStar, Greiner Bio-One, Frickenhausen, Germany) at a cell density of 10,000 and 30,000 cells per well, respectively. Once confluency of ±80% was reached (7 ± 1 days), the cells were exposed to CTX (and SMZ, TMP) using penicillin-streptomycin-free medium for 24 h. All experiments contained control cells unexposed to any reagent.
2.5 Cytotoxicity assay
To evaluate the cytotoxic effects and determine safe concentrations of CTX on the BeWo cell line, a broad range of SMZ, TMP, and CTX concentrations was initially tested. The cytotoxic effects of these antibiotics were investigated by measuring Lactate Dehydrogenase (LDH) leakage from cells into the cell culture medium using the CytoTox 96® Non-Radioactive Cytotoxicity Assay Kit (Promega Corporation, Madison, WI, United States) in 96-well flat-bottom plates. Four antibiotic concentrations, including 100, 200, 300, 400 μg/mL for SMZ, 25, 50, 100, 200 μg/mL for TMP, and 25, 50, 100, 200 μg/mL for CTX, were investigated to determine the acute cytotoxicity effect (24 h exposure). The concentration range for 24 h exposure was selected from a broader preliminary range and based on estimated human serum levels (; ). To investigate the cytotoxicity of chronic exposure to SMZ, TMP, or CTX, BeWo cells were treated for 5 days with the highest non-toxic concentrations determined from acute antibiotic exposure, followed by treatment with a range of lower concentrations. Every 24 h, 100 µL of the supernatant was gently removed and replaced with fresh medium containing the same antibiotic concentration. Considering the LDH instability during freeze-thaw cycles, LDH release was measured directly, according to the manufacturer’s instructions. The chronic cytotoxicity was calculated from the added LDH absorbance values of 5 days and using the formula (cytotoxicity (%) = (E/M) × 100), where E represents the experimental LDH release, and M represents the maximum LDH release. Maximum LDH release was determined by incubating positive control cells with a standard lysis buffer, Triton X-100. In addition, day-specific cytotoxicity was also calculated during chronic exposure (5 days). The LDH release was quantified by measuring absorbance at 490 nm using the GloMax Discover microplate reader (Promega Corporation).
2.6 RNA sequencing
2.6.1 Bulk RNA sequencing
Bulk RNA sequencing was performed on BeWo cells following 24-h exposure to SMZ (200 μg/mL), TMP (50 μg/mL), or CTX (50 μg/mL), as well as a DMSO (0.1%) control and an untreated control. Total RNA was extracted using the SV Total RNA Isolation System (Promega Corporation), and the RNA quantity and integrity were analyzed with the Agilent Fragment analyzer. Furthermore, bulk RNA sequencing was also performed on mouse placental tissue collected from control and CTX-treated dams. Total RNA was isolated from placental samples by the sequencing provider according to standard proprietary protocols. RNA quantity and integrity were assessed by the provider before library preparation and sequencing. The mRNA library construction and paired-end sequencing were conducted with a DNA nanoball and polymerase-based stepwise sequencing system (DNBSEQ) in BGI (Shenzhen, China). The paired-end FASTQ files were checked for adaptor sequences and poor-quality bases and short read length with Fastp (v.0.23.2) using the following parameters (-q 20 –L 50) (). Quality-assured trimmed reads were mapped to the GRCh38 assembly of the human genome using the splice-aware mapper Hisat2 (v.2.2.1) (Kim et al., 2015). The overall mappability in all samples was above 96 percent for ∼40 to 50 million 150bp reads. The raw count matrix was generated by feature Counts using GRCh38. p14 V44 human gene annotation file (Liao et al., 2014). Gene counts were normalized, and differential gene expression (DEG) analysis was performed with the DESeq2 package in R (v.4.3.1) (Love et al., 2014). The principal component analysis (PCA) was performed on VST-normalized gene count data for better interpretation of the expression-based similarities and variations across samples. A gene was considered as differentially expressed only if it was statistically significant (p-adj <0.05) and |log2| fold change was >0.5. This threshold was selected to retain genes with moderate but potentially biologically relevant changes in expression that would otherwise be excluded under more stringent criteria (e.g., |log2FC| ≥ 1). Heatmaps were generated on the DESeq2 normalized counts, and a z-score transformation was done before visualization.
2.6.2 Over-representation and gene set enrichment analysis
Query DE gene lists obtained from different comparison groups were subjected to over-representation analysis using enrichR (Kuleshov et al., 2016), a web-based tool for gene set enrichment, to identify biological pathways and functional categories over-represented among the DEGs. The msigdbr R package (v.1.10.0) was used to retrieve functional gene sets and their member genes for different categories, including C2 for KEGG, Reactome, and C5 for Gene Ontology (MF; molecular function, CC; cellular component, and BP; biological processes) (). Significantly represented pathways (p-adj <0.05) and gene ontologies were extracted and compared between different in vitro groups. The ClusterProfiler (v.4.8.3) package was used for the gene set enrichment analysis (GSEA) (Wu et al., 2021). Genes were ranked by a signed ranking metric (Log2FC), and gene ontology and pathway analysis were done with the following parameters (nPerm = 10,000, minGSSize = 3, maxGSSize = 800, pvaluecutoff = 0.05, and pAdjustMethod = “BH”). Significantly enriched pathways (p < 0.05) were identified and further examined by Western blot and qPCR with respect to their biological relevance.
2.6.3 Partial least squares-discriminant analysis of murine placental transcriptomes
Supervised multivariate analysis using Partial Least Squares-Discriminant Analysis (PLS-DA), and sparse PLS-DA was performed on transcriptome data from the in vivo experiment using the mixOmics package (Rohart et al., 2017) to identify latent components and features that discriminate between experimental groups (CTX-treated from untreated control). Variance-stabilized expression values obtained using the DESeq2 “vst” function were used as input for this analysis. Due to the small sample size (N = 4), the model showed overfitting under leave-one-out cross-validation, as indicated by a negative Q2. However, a negative Q2 does not invalidate the exploratory use of PLS-DA for feature prioritisation; it indicates that the model is not suitable for predictive classification. The model achieved good training-set discrimination (high R2Y = 69.2% and 25.1% across the two components) but lacked predictive generalisability. Accordingly, any features identified by this method should be considered exploratory and require validation in future studies with larger sample sizes and complementary molecular analysis.
2.7 TEER measurement and paracellular tracer flux assay
To investigate the effects of the SMZ, TMP, and CTX on the functioning of the in vitro placental barrier, transepithelial electrical resistance (TEER) measurements and a paracellular dye flux assay were performed. BeWo cells were seeded at a cell density of 30,000 live cells per insert onto CoStar polyester membrane Transwell 6.5 mm inserts with 0.4 µm pores (Corning, Kennebunk) in a 24-well plate. Once the cells reached a confluent monolayer (10 ± 1 days), they were exposed to SMZ, TMP, or CTX for 24 h from apical and basolateral compartments. The integrity of the monolayer was assessed by measuring TEER at time points 0 h and 24 h post-exposure using the Millicell ERS-2 Volt-Ohm meter (Millipore, Temecula, CA, United States). Permeability of the BeWo cell monolayer was evaluated by adding 100 μg/mL of membrane-permeable 4 kDa fluorescein isothiocyanate-dextran (FITC-D, Sigma-Aldrich) to the apical compartment only. After 4 h of incubation, 50 µL of basolateral medium was collected, and fluorescence intensity was measured with a GloMax Discover microplate reader (Promega Corporation) at excitation and emission wavelengths of 485 and 520 nm, respectively. For the FITC-D permeability assay, background fluorescence was determined using cell culture medium without FITC-D (blank control), and this value was subtracted from all experimental samples to correct for baseline signal.
2.8 RNA isolation and qPCR
To assess mRNA expression, BeWo cells were seeded in 24-well transwell plates as described above and exposed for 24 h to SMZ, TMP, or CTX. Cells were lysed in 175 µL of RNA lysis buffer containing β-mercaptoethanol, and total RNA was extracted using the SV Total RNA Isolation System (Promega Corporation). For in vivo analyses, mouse placentas were collected on gestational day 19, snap-frozen in liquid nitrogen, and stored at −80 °C until processing. Placental tissues were homogenized in the same lysis buffer using a Precellys® 24 homogenizer (Bertin Technologies, France), and RNA isolation was performed following the manufacturer’s protocol. The RNA content was determined using the Nanodrop One/OneC Spectrophotometer (Thermo Fisher Scientific, Madison, WI, United States). The purity of RNA samples was assessed using the 260/280 nm and 260/230 nm absorbance ratios, with ratios above 2 considered indicative of high purity. Reverse transcription of the mRNA samples into cDNA was conducted using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, United States) and the T100 Thermal Cycler (Bio-Rad Laboratories). Quantification of cDNA samples was performed using SYBR Green qPCR. The reaction mixtures were prepared in a 96-well hard-shell PCR plate (Bio-Rad Laboratories), and 1 µL of the appropriate cDNA sample was added to each well. Amplifications were performed using the CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories). The selected primers were commercially synthesized (Biolegio, Nijmegen, Netherlands), and mRNA expression levels were measured relative to the expression of the housekeeping gene β-actin and RPL13A (Supplementary Table S1).
2.9 Protein isolation and western blot
Western blot analysis was performed to assess the activation of Extracellular Signal-Regulated Kinase (ERK) signaling in both human BeWo placental cells and mouse placental tissue. For in vitro cell analysis, BeWo cells were seeded in 24-well plates, as previously described, and exposed to SMZ, TMP, or CTX for 24 h. Cells were lysed with ice-cold Pierce™ RIPA buffer (Thermo Scientific, Rockford, IL, United States) containing protease inhibitors (Roche Diagnostics, Mannheim, Germany) and phosphatase inhibitors (Thermo Scientific), followed by incubation on ice for 30 min. For in vivo analysis, mouse placentas were collected on gestational day 19, snap-frozen in liquid nitrogen, and stored at −80 °C. Tissues were homogenized in the same lysis buffer using a Precellys® 24 tissue homogenizer (Bertin Technologies) and processed under identical conditions. For both models, lysates were centrifuged at 14,000 × g for 15 min at 4 °C, and supernatants were collected. Total protein concentrations were determined using the Pierce™ BCA protein assay kit (Thermo Scientific). Equal amounts of denatured protein were separated by Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) using Mini-PROTEAN TGX and Criterion™ TGX Gels (4%–20%, Bio-Rad Laboratories) and transferred onto Polyvinylidene fluoride (PVDF) membranes using the Trans-Blot Turbo Transfer System (Bio-Rad Laboratories). Membranes were blocked for 1 h at room temperature in blocking buffer (0.1% (v/v) Tween-20 in PBS and 5% (w/v) milk proteins), then incubated overnight at 4 °C with primary antibodies against ERK1/2 (4695, Cell Signaling Technology, Danvers, MA, United States) and phosphorylated ERK1/2 (9101, Cell Signaling Technology) diluted in blocking buffer. After washing with PBS-T, membranes were incubated with HRP-conjugated secondary antibodies (Dako, Glostrup, Denmark) at a 1:3,000 dilution for 1 h at room temperature. Chemiluminescent detection was performed using Clarity™ Western Enhanced Chemiluminescence (ECL) Substrate (Bio-Rad Laboratories), and signals were captured using the ChemiDoc™ MP Imaging System (Bio-Rad Laboratories). Band intensity was quantified using ImageJ software (v.1.54G), and normalization was performed using Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control (monoclonal mouse anti-human GAPDH, 60004-1-Ig, Proteintech, Manchester, United Kingdom). Protein expression levels were expressed as fold change (FC) relative to the control group.
2.10 Enzyme-linked immunosorbent assay
Interleukin-6 (IL-6) protein levels were quantified in both in vitro and in vivo samples using enzyme-linked immunosorbent assay (ELISA). For in vitro analysis, BeWo cells were initially seeded at 30,000 cells per well and exposed to SMZ, TMP, or CTX for 24 h. Following exposure, the culture supernatants were collected and analyzed for IL-6 concentration using a commercial ELISA kit (Invitrogen, San Diego, CA, United States), using the manufacturer’s protocol. For in vivo analysis, IL-6 concentrations in amniotic fluid collected from CTX-treated and control mice were measured using a murine ELISA kit, following the manufacturer’s instructions (Promega Corporation). For ELISAs performed on in vitro and in vivo samples, 100 μL of each sample was used without further dilution. The absorbance at 450 nm was measured using a GloMax Discover microplate reader (Promega Corporation), and concentrations were calculated based on standard curves prepared from the kit-provided standards.
2.11 Statistics
Statistical analysis was performed using GraphPad Prism version 10.4.1 (627). Data normality was assessed by the Shapiro-Wilk test. Comparisons among multiple groups were conducted using one-way Analysis of Variance (ANOVA), followed by a Bonferroni multiple-comparison post hoc test. Comparisons between two independent groups were performed using an unpaired two-tailed Student’s t-test. All results are shown as mean ± Standard Error of the Mean (SEM), and differences were considered statistically significant at p < 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). RNA-sequencing related statistical analyses were performed using R software, as already described in the corresponding methods section.
3 Results
3.1 Co-trimoxazole induces reproductive toxicity in a murine pregnancy model
Figure 1A illustrates the experimental procedure of CTX exposure to pregnant mice. Pregnant mice received CTX via oral gavage during the first (GD1-GD6) and last 6 days (GD13-GD18) of pregnancy. On GD19, the effects of CTX on gestational body weight, litter size, fetal resorption, and uterine weight were analyzed. As shown in Figure 1B, the body weight remained unaffected in CTX-treated pregnant mice compared to control mice. While the increase in observed resorption in CTX-treated pregnant mice was not statistically significant (Figure 1C), these mice exhibited a significantly reduced litter size compared to the control group (p < 0.05) (Figure 1D). Furthermore, exposure to CTX significantly reduced the uterine weight (p < 0.05) compared to control pregnant mice (Figure 1E). To further investigate the possible molecular mechanisms underlying the observed effect of CTX on reproductive outcomes, transcriptomic profiling of murine placental tissue was conducted. Initial data from bulk RNA-sequencing of placenta samples, based on an unsupervised PCA, revealed substantial overlap between the control and CTX groups, indicating limited discriminatory power, suggesting that DEGs could not be clearly identified (Supplementary Figure S1). Given that the control and CTX groups were not distinctly segregated along the principal components, PLS-DA, a supervised multivariate method to enhance class separation, was applied. PLS-DA distinguished between control and CTX groups with clear clustering along the first two components, which represent the main axes of variation used for group separation (Figure 1F). A subset of genes contributing to the separation between control and CTX groups was identified via PLS-DA. Among these, thirteen genes with reported roles in placental function and reproductive toxicity were highlighted based on literature evidence. As depicted in Figure 1G, these genes showed altered expression in CTX-treated mice compared to control mice. The expression of Slc43a2, Nos3, Abcc4, IL12rb2, Plekhg3, Gpr84, Gtse1, and Igfbp5 was increased in CTX-treated mice compared to control mice, while Bmpr2, Cdkn1b, Slc13a1, Atf2, and Ccna1 expression was decreased. This exploratory transcriptomic analysis identified CTX-associated placental gene expression patterns that may contribute to altered reproductive outcomes, rather than establishing definitive mechanistic causality.
FIGURE 1
3.2 Co-trimoxazole induces cytotoxic effects in BeWo cells
The cytotoxicity of CTX, SMZ, and TMP in the human placental epithelial cell line (BeWo) was determined in vitro by measuring lactate dehydrogenase (LDH) leakage into the cell culture supernatant, as an indicator of compromised cell membrane integrity. As shown in Figure 2A, a significant increase in LDH leakage was observed with rising concentrations of SMZ, indicating cytotoxicity at 400 μg/mL (p < 0.01) after 24 h of exposure. Furthermore, increasing concentration of TMP led to a significant rise in LDH leakage, with 100 μg/mL (p < 0.05) and 200 μg/mL (p < 0.01) identified as cytotoxic (Figure 2B). CTX concentrations of 100 μg/mL (p < 0.01) and 200 μg/mL (p < 0.0001) were determined to be significantly cytotoxic after 24 h exposure compared to unexposed control cells (Figure 2C). SMZ (200 μg/mL), TMP (50 μg/mL), and CTX (50 μg/mL) were selected as non-toxic concentrations for the remaining experiments. Notably, CTX and SMZ showed cytotoxic effects even at lower concentrations after chronic exposure (5 days) to the BeWo cell line (Supplementary Figure S2).
FIGURE 2
3.3 Co-trimoxazole induces differential gene expression in BeWo cells
Total RNA was isolated from BeWo cells exposed to CTX (50 μg/mL), SMZ (200 μg/mL), and TMP (50 μg/mL) for 24 h. Subsequently, bulk RNA-sequencing was conducted using DNBSEQ technology for genome-wide gene expression analysis (Figure 3A). As shown in Figure 3B, PCA revealed distinct segregation among untreated control cells, cells exposed to SMZ, TMP, CTX, or DMSO (vehicle control), occupying different regions in the PCA plot. This was shown by the first principal component (PC1) and second principal component (PC2), which accounted for 41.36% and 13.5% of the variation, respectively, indicating differential gene expression profiles. As depicted in Figure 3C, a Venn diagram was generated to compare the sets of DEGs across SMZ, TMP, or CTX treatments. The analysis revealed that 190 genes (6.3%) were altered, not only by CTX exposure, but also by CTX’s individual components, SMZ and TMP. However, CTX uniquely affected 936 genes (30.9%), while 752 genes (24.8%) were affected by SMZ, and 601 genes (19.8%) by TMP. Figures 3D–F shows volcano plots comparing each antibiotic treatment to untreated controls, revealing biologically relevant genes to the ERK pathway and cell-cell junction complex, including MAPK3 and several dual-specificity phosphatases (DUSPs), key negative regulators of the ERK/MAPK signaling pathway (De Roo et al., 2025), as well as TJ-related genes. In SMZ-treated BeWo cells (Figure 3D), IL-6 was strongly downregulated, along with MAPK-related genes such as DUSP1, DUSP4, DUSP5, DUSP7, and DUSP9, as well as TJ-related genes like claudin-19 (CLDN19). TMP treatment (Figure 3E) elicited a similar pattern with consistent downregulation of IL-6, DUSP4, DUSP5, DUSP7, DUSP9, and CLDN19. In CTX-treated cells (Figure 3F), IL-6, DUSP4, and CLDN19 were also notably downregulated compared to the untreated control cells. Together, these findings indicate a common modulation of IL-6, MAPK signaling, and TJ-related genes across all treatments.
FIGURE 3
3.4 Co-trimoxazole alters the cell-cell junctional network and disrupts barrier integrity in BeWo cells
Cell-cell junctions, especially TJs and AJs, connect neighboring cells to the cytoskeleton, forming a cohesive network throughout placental tissue (Leach et al., 2000) (Figure 4A). Exposure of BeWo cells to CTX, or its individual components SMZ or TMP, for 24 h altered the gene expression associated with the junctional complex, resulting in enrichment of the cell-cell junction gene set among the top pathways in Over Representation Analysis (ORA) of Gene Ontology Cellular component (GO-CC) database (Figures 4B–D). GSEA analysis using GO-CC datasets revealed that the cell-cell junction gene set was significantly enriched only in CTX-treated BeWo cells (Figure 4E). The Normalized Enrichment Score (NES) of −1.541 indicates that the gene set members were predominantly positioned at the bottom of the ranked list, reflecting their downregulation in CTX-treated cells compared to control. A distinct expression pattern was observed between CTX-treated and control cells, with widespread downregulation of TJ and AJ-related genes in CTX-treated cells, including CLDN19. However, a small subset of TJ and AJ-related genes was notably upregulated in the CTX-treated cells compared to control cells, such as CLDN4 and CLDN12 (Figures 4F,G). To evaluate the functional impact of CTX, as well as individual treatments with SMZ and TMP, on the BeWo cell monolayer barrier, TEER and FITC-D permeability were assessed using a Transwell insert model (Figure 4H). The mean TEER value for the untreated confluent BeWo monolayer was 70.4 ± 3.19 Ω.cm2 and was defined as 100% in Figure 4I. As depicted in Figure 4I, CTX significantly decreased TEER values (p < 0.0001), followed by SMZ, which also caused a significant but less pronounced reduction after 24 h of incubation (p < 0.01). In contrast, TMP did not significantly affect TEER values. Consequently, CTX exposure resulted in a significant (p < 0.001) increase in paracellular transport of FITC-D across the BeWo monolayer from the apical to the basolateral compartment. However, after exposure to SMZ and TMP, the paracellular transport of FITC-D did not change significantly (Figure 4J).
FIGURE 4
3.5 Co-trimoxazole induces downregulation of DUSPs and activation of the ERK pathway (MAPK1/3) in BeWo cells
As shown in Figures 5A–C, exposure of BeWo cells to SMZ, TMP, or CTX induced differential expression of MAPK-related genes, resulting in the enrichment of the MAPK signaling pathway among the top pathways in ORA analysis of DEGs using the KEGG database. Although GSEA analysis showed that treatment of BeWo cells with SMZ and TMP alone did not affect the MAPK signaling pathway, CTX significantly (p.adjusted <0.0001) induced differential expression of involved genes in the Raf-independent MAPK1/3 (ERK2/1) pathway. The NES of 2.3 shows the downregulation of Raf-independent MAPK1/3 (ERK2/1 pathway) genes upon CTX exposure (Figure 5D). The curated heatmap of genes affected by CTX in the Raf-independent MAPK1/3 activation pathway gene set indicated downregulation of enriched genes, including MAPK3/ERK1 and MAP2K1, an ERK-specific activator via dual-specific kinase activity (Figure 5E). Furthermore, DUSPs, such as DUSP1, DUSP4, DUSP5, DUSP7, and DUSP9, were also downregulated following CTX exposure. Moreover, IL-6 signal transducer (IL-6ST) and Janus kinase 1 (JAK1) were downregulated in CTX-treated cells compared to control, all of which play a pivotal role in ERK activation. As depicted in Figure 5F, although SMZ, TMP, or CTX did not significantly affect the protein expression of MAPK1/3 (ERK2/1) in BeWo cells, SMZ (p < 0.05) and CTX (p < 0.01) increased MAPK1/3 (ERK2/1) phosphorylation level, indicating activation of the ERK pathway (Figure 5G). The ERK-activating effect of CTX observed in vitro in BeWo cells was not recapitulated in vivo in mouse placental tissue; CTX exposure did not cause a significant change in ERK phosphorylation relative to controls (Supplementary Figure S3).
FIGURE 5
3.6 Co-trimoxazole suppresses IL-6 expression in BeWo cells and in murine placental tissue
The progression of pregnancy and placental development depends on trophoblast cell activity, which is partially coordinated by cytokines and growth factors, including IL-6. GSEA analysis indicated that treatment of BeWo cells with SMZ and TMP alone did not affect the IL-6 signaling pathway, whereas CTX exposure resulted in a significant enrichment of IL-6 pathway-related genes (q-value = 0.04367) with a NES of −1.91 (Figure 6A). The negative NES indicates that IL-6 pathway genes are predominantly downregulated in the CTX-treated cells, suggesting that CTX suppresses IL-6 signaling activity in BeWo cells. Figure 6B shows the gene-gene interaction network of the IL-6 signaling pathway, illustrating changes in IL-6 family signaling induced by CTX compared to control. The greatest fold change was observed for IL-6 itself, which appears in deep red among all genes in the network. The curated heatmap of IL-6 signaling-related genes altered by CTX exposure is shown in Figure 6C. The heatmap illustrates components of the IL-6/gp130 cytokine network, including key elements of the canonical IL-6 pathway (IL-6, IL6ST, JAK1, STAT1, SOCS3) and related IL-6 family members (CTF1 and LIFR). As depicted in Figures 6D,E, not only CTX but also SMZ and TMP diminished the IL-6 expression in BeWo cells at both the transcript and protein levels. To assess the translatability of CTX’s effect on IL-6 at the maternal-fetal interface, IL-6 protein levels in amniotic fluid and IL-6 gene expression in placental tissue were quantified in pregnant mice treated with CTX during pregnancy (Figure 6F). As depicted in Figures 6G,H, CTX exposure during pregnancy significantly decreased the IL-6 protein (p < 0.01) and mRNA (p < 0.05) expression in amniotic fluid and placenta, respectively.
FIGURE 6
3.7 Co-trimoxazole suppresses IL-6 expression in BeWo cells independently from ERK signaling
To investigate the role of the ERK pathway in regulating IL-6 levels following SMZ, TMP, or CTX exposure in BeWo cells, we assessed ERK protein phosphorylation and IL-6 production with or without the ERK-specific inhibitor PD98059 (ERKi). Western blot analysis showed that SMZ, TMP, and CTX increased ERK phosphorylation (p-ERK) compared with control cells, which was effectively inhibited by ERKi (Figure 7A). ELISA analysis demonstrated that all treatments significantly (p < 0.0001) reduced IL-6 levels compared with controls (Figures 7B–D). Importantly, inhibition of ERK signaling did not restore IL-6 levels; instead, co-treatment with ERKi further reduced IL-6 levels.
FIGURE 7
4 Discussion
Clinical guidelines advise that women who meet criteria for CTX prophylaxis should continue therapy throughout pregnancy, as the risk of life-threatening infections outweighs the potential risk of fetal malformations (; Organization, 2021). CTX, the co-formulated antibiotic of TMP and SMZ, remains clinically indicated in certain high-risk pregnancy situations, including gestational UTI, as well as an HIV-positive pregnancy (; ; ).
Despite longstanding concerns, such as congenital malformation and maternal folic acid deficiency that might be followed by neonatal complications like neural tube defects and urinary tract defects, oral clefts (Smilack, 1999), the existing evidence does not justify completely avoiding CTX during pregnancy.
Although both TMP and SMZ cross the placenta, reaching fetal concentrations of 70%–100% of maternal levels (), there is not sufficient research examining how these antibiotics might impact placental tissue and function, underscoring the need for further studies in this area. Therefore, in this study, we investigated the effects of CTX and its components, TMP and SMZ, on the placenta using an in vivo murine pregnancy model and a BeWo cell-based in vitro placental epithelium model.
CTX exposure during pregnancy significantly reduced litter size and uterine weight, with increased resorption (Figure 1), while maternal body weight remained unaffected. These outcomes are likely indicative of impaired implantation and/or suboptimal placental development, as CTX exposure was associated with alterations in placental gene expression related to cell cycle regulation, nutrient transport, and vascularization (Winterhager and Gellhaus, 2017; Jansson et al., 2006; Huang et al., 2021; Torry et al., 2007).
The defects observed with CTX in the current study align with previously reported effects of SMZ and CTX on fetal growth and ovarian development (L et al., 2022; Reel et al., 1992; Saberi et al., 2017). Animal models have also reported that antibiotic use during pregnancy, including β-lactams, macrolides, and norfloxacin, can induce reproductive toxicity (Nathanson et al., 2000; Karabulut et al., 2008; ). In addition, gestational exposure to other antibiotics, like amoxicillin and metronidazole, has been associated with reduced fetal survival and impaired fetal growth, including increased fetal resorption and decreased litter size (; ; Huang et al., 2025).
Within this framework, the placenta represents a critical and frequently examined target due to its central role in supporting fetal growth and mediating maternal-fetal exchange (Jansson, 2016). Alterations in placental structure or gene expression can contribute to adverse pregnancy outcomes, highlighting the importance of investigating how gestational antibiotic exposure affects the placenta.
To investigate the mechanism of CTX-induced reproductive toxicity, placental samples from CTX-treated and control mice were analyzed using transcriptomics with a supervised approach. A total of thirteen genes, potentially involved in the reproductive toxicity observed in CTX-treated mice, showed altered expression levels in the placenta compared to controls. Among these, Bmpr2, Cdkn1b, Slc13a1, Atf2, and Ccna1 were downregulated, whereas Slc43a2, Nos3, Abcc4, IL12rb2, Plekhg3, Gpr84, Gtse1, and Igfbp5 were upregulated. These genes are biologically relevant to the placental function and are mechanistically linked to CTX-induced reproductive toxicity. They likely play pivotal roles in supporting fetal growth through diverse functions, including amino acid transport, placental vascularization, toxin efflux, protection against xenobiotics, immune regulation, junctional stability, and trophoblast invasion and differentiation. Modulation of these genes’ expression indicates that CTX exposure may impair key regulators of placental development and the maintenance of maternal-fetal homeostasis (Venkataraman and Kuo, 2005; Schulze et al., 2022; Xie et al., 2021; Liu et al., 2019; Han et al., 1996; ; Owaydhah et al., 2021; Krause et al., 2011; Joshi et al., 2016; Zourbas et al., 2001).
Given the alterations in placental gene expression related to reproductive toxicity observed in our in vivo murine pregnancy model, the human BeWo trophoblast cell line was employed as an in vitro model (Seyed Toutounchi et al., 2019) to examine the effects of CTX on the placental barrier.
The placental barrier is crucial for protecting the fetus by acting as a physical barrier against harmful agents (Kirkpatrick et al., 2025). Although antibiotics are widely studied for their effects on intestinal barrier integrity (; Ran et al., 2020; ; Tulstrup et al., 2015; ), evidence regarding their impact, especially that of CTX, on placental barrier integrity remains limited.
Transcriptomic analysis of BeWo cells after CTX exposure revealed that CTX impaired the placental trophoblast barrier integrity in vitro, as demonstrated by altered expression of TJ and AJ genes, including CLDN19, which play pivotal roles in maintaining placental integrity (Leach et al., 2000; Miranda et al., 2019; Pidoux et al., 2010). Although some TJ and AJ genes were upregulated following CTX exposure, most were downregulated.
This mixed expression profile suggests barrier dysregulation rather than coordinated junctional maintenance. The increased expression of certain junction-related genes (CLDN4 and CLDN12) may represent a compensatory or stress-related attempt to maintain placental barrier integrity, whereas the reduced expression of key structural components such as CLDN19 is likely to compromise the placental barrier. Consistent with this molecular profile, CTX exposure decreased TEER values and increased FITC-D permeability across BeWo cell monolayers, confirming a functional disruption of placental barrier integrity. While the adverse effects of antibiotics, including CTX, are commonly attributed to microbiome-mediated mechanisms, our findings demonstrate that CTX can also directly disrupt placental trophoblast barrier function in a microbiome-free in vitro model (; ; Panzer et al., 2023).
Besides CTX’s critical effects on cell-cell junctions in BeWo monolayers, CTX also activated the MAPK/ERK signaling pathway, as indicated by increased ERK1/2 phosphorylation. Proper placental barrier formation requires tightly regulated ERK/MAPK pathway activity, which is critical for normal growth, differentiation, and morphogenesis of placental cells (Nadeau and Charron, 2014; ; ). CTX-induced activation of the ERK/MAPK pathway may be attributed to its suppressive impact on DUSP family gene expression in BeWo cells, particularly DUSP5, DUSP7, and DUSP9, which normally dephosphorylate and inactivate ERK to maintain appropriate pathway activity (; Kidger et al., 2017; Urness et al., 2008). Although other DUSPs suppressed by CTX may also contribute to ERK dephosphorylation (Tubita et al., 2025), their precise roles remain to be determined.
While our study is the first to demonstrate CTX-induced activation of the ERK pathway in BeWo placental trophoblast cells, other antibiotics, like colistin and macrolides, have been shown to modulate ERK signaling in other cell types, including bronchial epithelial cells and macrophages (Shinkai et al., 2006; Wang et al., 2019).
The observed disruptive effect of CTX on placental trophoblast barrier integrity may be associated with changes in ERK signaling, which has been implicated in the regulation of TJ and AJ gene expression (Mullin et al., 2005; Lipschutz et al., 2005; ; ). Furthermore, proper ERK signaling is required for normal placental growth, differentiation, and morphogenesis (Nadeau and Charron, 2014). ERK1/2 activation can disrupt the bronchial epithelial barrier by downregulating E-cadherin, Z O -1, Occludin, and CLDN5 (Zhou et al., 2024). Furthermore, ERK1/2-STAT3 pathway activation reduces TJ protein expression, lowers TEER, and increases permeability in nasal epithelial cells (Wu et al., 2024) with similar barrier-disruptive effects observed in the alveolar epithelium (Ruan et al., 2022).
Although CTX activated ERK signaling in BeWo cells in vitro, this effect was not observed in placental tissue in vivo. This difference likely results from compensatory regulatory mechanisms, cellular complexity, and differences in drug exposure between simplified in vitro conditions and the in vivo maternal-placental environment.
It is worth noting that ERK can also be strongly activated by pro-inflammatory cytokines (). In the BeWo cell model, CTX suppressed IL-6 signaling, significantly reducing IL-6 expression at both the transcript and protein levels, while TNFα and IL-8 remained unaffected (Supplementary Figure S4). Furthermore, CTX exposure during pregnancy diminished the IL-6 levels in both amniotic fluid and placenta from in vivo murine pregnancy model.
IL-6 is a pleiotropic cytokine abundantly produced by placental trophoblasts and decidual cells at the maternal-fetal interface, where it plays an important role in placental function and immune regulation during pregnancy (Jovanović and Vićovac, 2009). IL-6 supports placental homeostasis by promoting trophoblast proliferation, migration, and invasion (Vilotić et al., 2022). A controlled pro-inflammatory environment during pregnancy is essential for successful implantation and placental development (). While our study demonstrated a local maternal-fetal suppressive effect of CTX on IL-6 expression, a mouse pregnancy study with broad-spectrum antibiotics reported reduced systemic IL-6 production by splenocytes upon lipopolysaccharide stimulation ().
Furthermore, clarithromycin reduced IL-6 concentrations in amniotic fluid during intra-amniotic infection, similar to the effect of CTX in our study, although this effect may be secondary to reduced bacterial burden or the immunomodulatory properties of the antibiotic (Kacerovsky et al., 2020). The ERK and IL-6 signaling pathways share a bidirectional relationship, where IL-6 activates the ERK pathway to promote proliferation, inflammation-induced ERK activation can, in turn, enhance IL-6 production (Leonard et al., 1999; Kitanaka et al., 2019). In our study, CTX activated ERK signaling in vitro without elevating IL-6 levels. Moreover, co-treatment of BeWo cells with an ERK-specific inhibitor and CTX further suppressed IL-6 release, indicating that CTX modulates the IL-6 pathway independently of ERK signaling, suggesting that alternative pathways, such as NF-κB signaling, may underlie the observed reduction in IL-6 (Liu et al., 2017). As previously mentioned, CTX is a fixed-dose combination of SMZ and TMP. Although each component can be prescribed individually, particularly TMP for uncomplicated UTI, the combination remains the most commonly used and clinically effective formulation due to its synergistic antibacterial activity.
Considering this clinical relevance, the present study primarily focused on the combined effect of CTX, especially in vivo murine experiments. Nevertheless, in the in vitro assays, both CTX and its individual components, SMZ and TMP, were evaluated to allow for direct comparison of their effects.
All three compounds, CTX, SMZ, and TMP, exhibited cytotoxicity toward placental trophoblast BeWo cells. However, CTX induced stronger cytotoxic effects at lower concentrations compared with either component alone. Transcriptomic analysis further revealed that CTX altered a larger proportion of DEGs (30.9%) than SMZ (24.8%) or TMP (19.8%). ORA indicated enrichment of cell-cell junction-related pathways across all treatments, while GSEA identified this effect exclusively in CTX-exposed BeWo cells. Functionally, CTX was the only compound that significantly disrupted trophoblast barrier integrity in the transwell model. Moreover, although SMZ, TMP, and CTX increased ERK phosphorylation, a significant activation of ERK was observed only in CTX-treated cells. Notably, all three compounds significantly reduced IL-6 expression in BeWo cells. Collectively, these findings indicate that the combined formulation of CTX exerts a more pronounced and multifaceted disruptive effect on placental trophoblast function than either SMZ or TMP alone.
Despite providing novel insights into the gestational effects of CTX on placental function using both in vitro and in vivo models, this study has certain limitations that should be addressed. The BeWo cell model used in this manuscript is an accepted and employed placental trophoblast barrier model (Seyed Toutounchi et al., 2019; Poulsen et al., 2009; ), however, future studies using primary placental trophoblasts may provide greater physiological relevance. In addition, the in vivo experiments were conducted with a relatively small sample size (N = 4 per group), which may reduce statistical robustness and generalizability. In addition, placental genes associated with reproductive toxicity were identified using supervised PLS-DA based clustering for exploratory purposes only and require further validation by targeted approaches such as qPCR or WB.
It is also important to note that the microbiome, which was not examined in the current study, could provide additional insight into potential microbial influences on CTX-induced placental alterations. Another limitation is that the ERK signaling appears to contribute to the effects of CTX on trophoblast barrier integrity in vitro, but direct functional assessment of this pathway in BeWo cells, such as evaluating the impact of ERK inhibition on TEER value and TJs expression, was not performed. Such analyses could have provided deeper mechanistic insight into ERK-mediated regulation of placental barrier function that should be considered in future experiments. CTX-induced alterations in cell-cell junctions were detectable in vitro but not consistently observed in placental tissue in vivo, likely due to sample size or the greater cellular complexity and regulatory mechanisms present in the maternal-placental environment.
Taken together, our findings demonstrate that, despite CTX’s clinical benefits in treating maternal infections, CTX may pose potential risks during pregnancy by affecting both reproductive outcomes and placental health. In a murine model, CTX induced reproductive toxicity, while in vitro, CTX compromised placental barrier integrity, accompanied by activation of the ERK signaling pathway. Additionally, CTX suppressed IL-6 signaling within the placental environment, an effect that appeared to occur independently of ERK activation. These findings warrant heightened awareness regarding CTX use during pregnancy and support continued research into its placenta-specific molecular targets.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.
Ethics statement
The animal study was approved by Animal Welfare Body (AWB), Utrecht University, Utrecht, Netherlands. The study was conducted in accordance with the local legislation and institutional requirements.
Author contributions
MA: Conceptualization, Investigation, Writing – original draft, Formal Analysis. HS: Formal Analysis, Writing – review and editing. IACvV: Investigation, Writing – review and editing. ST: Writing – review and editing, Investigation. BvL: Writing – review and editing, Conceptualization. RvE: Conceptualization, Writing – review and editing. JG: Supervision, Writing – review and editing. GF: Writing – review and editing, Supervision. AH: Writing – review and editing, Conceptualization, Supervision. SB: Conceptualization, Writing – review and editing, Supervision.
Funding
The author(s) declared that financial support was received for this work and/or its publication. Financial support for this study was provided by Danone Nutricia Research. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
Conflict of interest
JG serves as the head of the Division of Pharmacology at Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, and holds partial employment with Danone Research and Innovation, Utrecht, Netherlands. BvL, is affiliated with Danone Research and Innovation, Utrecht, Netherlands, and holds a PI position at the University Medical Center, Utrecht, Netherlands. SB is partially funded by Danone Research and Innovation Center, Utrecht, Netherlands.
The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author JG declared that they were an editorial board member of Frontiers at the time of submission. This had no impact on the peer review process and the final decision
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2026.1800328/full#supplementary-material
References
1
AbdRabouM. A.AlrashdiB. M.AlruwailiH. K.ElmazoudyR. H.AlwailiM. A.OthmanS. I.et al (2023). Exploration of maternal and fetal toxicity risks for metronidazole-related teratogenicity and hepatotoxicity through an assessment in albino rats. Toxics11 (4), 303. 10.3390/toxics11040303
2
AboubakrM.ElbadawyM.SolimanA.El-HewaityM. (2014). Embryotoxic and teratogenic effects of norfloxacin in pregnant female albino rats. Adv. Pharmacol. Pharm. Sci.2014 (1), 924706. 10.1155/2014/924706
3
AdedejiW. (2016). The treasure called antibiotics. Ann. Ib. Postgraduate Medicine14 (2), 56–57.
4
BarnesK. B.StewardJ.ThwaiteJ. E.LeverM. S.DaviesC. H.ArmstrongS. J.et al (2013). Trimethoprim/Sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders. Int. J. Antimicrob. Agents.41 (6), 552–557. 10.1016/j.ijantimicag.2013.02.007
5
BawdonR. E.MaberryM. C.FortunatoS. J.GilstrapL. C.KimS. (1991). Trimethoprim and sulfamethoxazole transfer in the in vitro perfused human cotyledon. Gynecol. Obstet. Invest.31 (4), 240–242. 10.1159/000293167
6
BennerM.Lopez-RinconA.ThijssenS.GarssenJ.FerwerdaG.JoostenI.et al (2021). Antibiotic intervention affects maternal immunity during gestation in mice. Front. Immunol.12, 685742. 10.3389/fimmu.2021.685742
7
BetschartC.AlbrichW. C.BrandnerS.FaltinD.KuhnA.SurbekD.et al (2020). Guideline of the Swiss society of gynaecology and obstetrics (SSGO) on acute and recurrent urinary tract infections in women, including pregnancy. Swiss Med. Wkly.150, w20236. 10.4414/smw.2020.20236
8
BhuvaD.SmythG.GarnhamA. (2023). Msigdb: an ExperimentHub package for the molecular signatures database (MSigDB). R. Package Version1 (0).
9
BookstaverP. B.BlandC. M.GriffinB.StoverK. R.EilandL. S.McLaughlinM. (2015). A review of antibiotic use in pregnancy. Pharmacotherapy. J. Hum. Pharmacol. Drug Ther.35 (11), 1052–1062. 10.1002/phar.1649
10
BourkeC. D.GoughE. K.PimunduG.ShonhaiA.BerejenaC.TerryL.et al (2019). Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation. Sci. Transl. Med.11 (486), eaav0537. 10.1126/scitranslmed.aav0537
11
BrownG. R. (2014). Cotrimoxazole-optimal dosing in the critically ill. Ann. Intensive Care4 (1), 13. 10.1186/2110-5820-4-13
12
BuffetC.Hecale-PerlemoineK.BricaireL.DumontF.BaudryC.TissierF.et al (2017). DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers. PloS One12 (9), e0184861. 10.1371/journal.pone.0184861
13
CampioliC. C.Abu SalehO.MaraK. C.RiveraC. G. (2022). Observational study of the clinical utility of sulfamethoxazole serum level monitoring in the treatment of brain abscesses due to nocardia species. Medicine101 (9), e28951. 10.1097/MD.0000000000028951
14
CantaruttiA.ReaF.FranchiM.BeccalliB.LocatelliA.CorraoG. (2021). Use of antibiotic treatment in pregnancy and the risk of several neonatal outcomes: a population-based study. Int. J. Environ. Res. Public Health18 (23), 12621. 10.3390/ijerph182312621
15
CharronJ.BissonauthV.NadeauV. (2012). Implication of MEK1 and MEK2 in the establishment of the blood–placenta barrier during placentogenesis in mouse. Reprod. Biomedicine Online25 (1), 58–67. 10.1016/j.rbmo.2012.02.012
16
ChenY.-h.LuQ.SchneebergerE. E.GoodenoughD. A. (2000). Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras-transformed madin-darby canine kidney cells. Mol. Biology Cell11 (3), 849–862. 10.1091/mbc.11.3.849
17
ChenS.ZhouY.ChenY.GuJ. (2018). Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics34 (17), i884–i890. 10.1093/bioinformatics/bty560
18
ChenC.-M.ChouH.-C.YangY.-C. S. (2021). Maternal antibiotic treatment disrupts the intestinal microbiota and intestinal development in neonatal mice. Front. Microbiol.12, 684233. 10.3389/fmicb.2021.684233
19
CockerillI. I. I. F. R.EdsonR. S. (1991). “Trimethoprim-sulfamethoxazole,” in Mayo Clinic Proceedings (Elsevier).
20
CongX.KongW. (2020). Endothelial tight junctions and their regulatory signaling pathways in vascular homeostasis and disease. Cell. Signalling66, 109485. 10.1016/j.cellsig.2019.109485
21
CorralesM.Corrales-AcostaE.Corrales-RiverosJ. G. (2022). Which antibiotic for urinary tract infections in pregnancy? A literature review of international guidelines. J. Clinical Medicine11 (23), 7226. 10.3390/jcm11237226
22
CzajkowskiK.Broś-KonopielkoM.Teliga-CzajkowskaJ. (2021). Urinary tract infection in women. Menopause Review/Prz. Menopauzalny20 (1), 40–47. 10.5114/pm.2021.105382
23
DaiY.PengY.HuW.LiuY.WangH. (2024). Prenatal amoxicillin exposure induces developmental toxicity in fetal mice and its characteristics. J. Environ. Sci.137, 287–301. 10.1016/j.jes.2023.02.021
24
DaoudG.AmyotM.RassartE.MasseA.SimoneauL.LafondJ. (2005). ERK1/2 and p38 regulate trophoblasts differentiation in human term placenta. J. Physiology566 (2), 409–423. 10.1113/jphysiol.2005.089326
25
De GoffauM. C.LagerS.SovioU.GaccioliF.CookE.PeacockS. J.et al (2019). Human placenta has no microbiome but can contain potential pathogens. Nature572 (7769), 329–334. 10.1038/s41586-019-1451-5
26
de JongeL.BosH. J.van LangenI. M.de Jong-van den BergL. T. W.BakkerM. K. (2014). Antibiotics prescribed before, during and after pregnancy in the Netherlands: a drug utilization study. Pharmacoepidemiol. Drug Saf.23 (1), 60–68. 10.1002/pds.3492
27
DengF.LeiJ.QiuJ.ZhaoC.WangX.LiM.et al (2024). DNA methylation landscape in pregnancy-induced hypertension: progress and challenges. Reproductive Biol. Endocrinol.22 (1), 77. 10.1186/s12958-024-01248-0
28
De RooC.McLeanE.LiuR. (2025). DUSPs: an update on their activity regulation and roles in metabolic diseases. Curr. Opin. Physiology44, 100816. 10.1016/j.cophys.2025.100816
29
DjouadF.RackwitzL.SongY.JanjaninS.TuanR. S. (2009). ERK1/2 activation induced by inflammatory cytokines compromises effective host tissue integration of engineered cartilage. Tissue Eng. Part A15 (10), 2825–2835. 10.1089/ten.TEA.2008.0663
30
DudleyM. N.LevitzR. E.QuintilianiR.HickingbothamJ. M.NightingaleC. H. (1984). Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. Antimicrob. Agents Chemotherapy26 (6), 811–814. 10.1128/aac.26.6.811
31
FeinK. C.ArralM. L.KimJ. S.NewbyA. N.WhiteheadK. A. (2023). Placental drug transport and fetal exposure during pregnancy is determined by drug molecular size, chemistry, and conformation. J. Control. Release361, 29–39. 10.1016/j.jconrel.2023.07.029
32
FengY.HuangY.WangY.WangP.SongH.WangF. (2019). Antibiotics induced intestinal tight junction barrier dysfunction is associated with microbiota dysbiosis, activated NLRP3 inflammasome and autophagy. PloS One14 (6), e0218384. 10.1371/journal.pone.0218384
33
FordN.ShubberZ.JaoJ.AbramsE. J.FrigatiL.MofensonL. (2014). Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis. JAIDS J. Acquir. Immune Defic. Syndromes66 (5), 512–521. 10.1097/QAI.0000000000000211
34
GarciaT. M.van RoestM.VermeulenJ. L.MeisnerS.SmitW. L.SilvaJ.et al (2021). Early life antibiotics influence in vivo and in vitro mouse intestinal epithelium maturation and functioning. Cell. Molecular Gastroenterology Hepatol.12 (3), 943–981. 10.1016/j.jcmgh.2021.05.019
35
Garcia‐HernandezV.QuirosM.NusratA. (2017). Intestinal epithelial claudins: expression and regulation in homeostasis and inflammation. Ann. N. Y. Acad. Sci.1397 (1), 66–79. 10.1111/nyas.13360
36
Gonzalez-MariscalL.BetanzosA.NavaP.JaramilloB. E. (2003). Tight junction proteins. Prog. Biophys. Mol. Biol.81 (1), 1–44. 10.1016/s0079-6107(02)00037-8
37
González-MariscalL.TapiaR.ChamorroD. (2008). Crosstalk of tight junction components with signaling pathways. Biochim. Biophys. Acta, Biomembr.1778 (3), 729–756. 10.1016/j.bbamem.2007.08.018
38
GriffithO. W.ChavanA. R.ProtopapasS.MaziarzJ.RomeroR.WagnerG. P. (2017). Embryo implantation evolved from an ancestral inflammatory attachment reaction. Proc. Natl. Acad. Sci.114 (32), E6566–E6575. 10.1073/pnas.1701129114
39
GudeN. M.RobertsC. T.KalionisB.KingR. G. (2004). Growth and function of the normal human placenta. Thromb. Res.114 (5-6), 397–407. 10.1016/j.thromres.2004.06.038
40
GünzelD.YuA. S. (2013). Claudins and the modulation of tight junction permeability. Physiol. Reviews93 (2), 525–569. 10.1152/physrev.00019.2012
41
HanV.BassettN.WaltonJ.ChallisJ. R. (1996). The expression of insulin-like growth factor (IGF) and IGF-Binding protein (IGFBP) genes in the human placenta and membranes: evidence for IGF-IGFBP interactions at the feto-maternal interface. J. Clin. Endocrinol. and Metabolism81 (7), 2680–2693. 10.1210/jcem.81.7.8675597
42
Hernández-DíazS.WerlerM. M.WalkerA. M.MitchellA. A. (2000). Folic acid antagonists during pregnancy and the risk of birth defects. N. Engl. J. Medi.343 (22), 1608–1614. 10.1056/NEJM200011303432204
43
Hernández-DíazS.WerlerM. M.WalkerA. M.MitchellA. A. (2001). Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am. J. Epidemiolo.153 (10), 961–968. 10.1093/aje/153.10.961
44
HuangZ.HuangS.SongT.YinY.TanC. (2021). Placental angiogenesis in mammals: a review of the regulatory effects of signaling pathways and functional nutrients. Adv. Nutr.12 (6), 2415–2434. 10.1093/advances/nmab070
45
HuangJ.LiY.ZhangM.WuT.ZhangY.WangH. (2025). The impact of prenatal amoxicillin exposure at different doses, stages, and courses on offspring ovarian development. Mol. Med.31 (1), 261. 10.1186/s10020-025-01322-2
46
JanssonT. (2016). Placenta plays a critical role in maternal–fetal resource allocation. Proc. Natl. Acad. Sci.113 (40), 11066–11068. 10.1073/pnas.1613437113
47
JanssonN.PetterssonJ.HaafizA.EricssonA.PalmbergI.TranbergM.et al (2006). Down‐regulation of placental transport of amino acids precedes the development of intrauterine growth restriction in rats fed a low protein diet. J. Physiology576 (3), 935–946. 10.1113/jphysiol.2006.116509
48
JoshiA. A.VaidyaS. S.St-PierreM. V.MikheevA. M.DesinoK. E.NyandegeA. N.et al (2016). Placental ABC transporters: biological impact and pharmaceutical significance. Pharm. Research33 (12), 2847–2878. 10.1007/s11095-016-2028-8
49
JovanovićM.VićovacL. (2009). Interleukin-6 stimulates cell migration, invasion and integrin expression in HTR-8/SVneo cell line. Placenta30 (4), 320–328. 10.1016/j.placenta.2009.01.013
50
KacerovskyM.RomeroR.StepanM.StranikJ.MalyJ.PliskovaL.et al (2020). Antibiotic administration reduces the rate of intraamniotic inflammation in preterm prelabor rupture of the membranes. Am. J. Obstet. Gynecol.223 (1), 114. e1–114. e20. 10.1016/j.ajog.2020.01.043
51
KarabulutA.UysalI. I.AcarH.FazliogullariZ. (2008). Investigation of developmental toxicity and teratogenicity of macrolide antibiotics in cultured rat embryos. Anat. Histologia, Embryologia37 (5), 369–375. 10.1111/j.1439-0264.2008.00861.x
52
KemnicT. R.ColemanM. (2023). Trimethoprim Sulfamethoxazole.Treasure Island, FL: StatPearls Publishing.
53
KidgerA. M.RushworthL. K.StellzigJ.DavidsonJ.BryantC. J.BayleyC.et al (2017). Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling. Proc. Natl. Acad. Sci.114 (3), E317–E326. 10.1073/pnas.1614684114
54
KimD.LangmeadB.SalzbergS. L. (2015). HISAT: a fast spliced aligner with low memory requirements. Nat. Methods12 (4), 357–360. 10.1038/nmeth.3317
55
KirkpatrickM.MandalG.ElhadidyI.MarianiN.PriestleyK.ParianteC. M.et al (2025). From placenta to the foetus: a systematic review of in vitro models of stress-and inflammation-induced depression in pregnancy. Mol. Psychiatry30 (4), 1689–1707. 10.1038/s41380-024-02866-1
56
KitanakaN.NakanoR.SugiuraK.KitanakaT.NambaS.KonnoT.et al (2019). Interleukin-1β promotes interleulin-6 expression via ERK1/2 signaling pathway in canine dermal fibroblasts. PLoS One14 (7), e0220262. 10.1371/journal.pone.0220262
57
KrauseB.HansonM. A.CasanelloP. (2011). Role of nitric oxide in placental vascular development and function. Placenta32 (11), 797–805. 10.1016/j.placenta.2011.06.025
58
KuleshovM. V.JonesM. R.RouillardA. D.FernandezN. F.DuanQ.WangZ.et al (2016). Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res.44 (W1), W90–W97. 10.1093/nar/gkw377
59
LinJ.DingJ.DiX.SunW.ChenH.ZhangH. (2022). Association between prenatal antibiotics exposure and measures of fetal growth: a repeated-measure study. Ecotoxicol. Environ. Saf.244, 114041. 10.1016/j.ecoenv.2022.114041
60
LeachL.LammimanM. J.BabawaleM. O.HobsonS. A.BromilouB.LovatS.et al (2000). Molecular organization of tight and adherens junctions in the human placental vascular tree. Placenta21 (5-6), 547–557. 10.1053/plac.2000.0541
61
LeegwaterE.BaidjoeL.WilmsE. B.VisserL. G.TouwD. J.de WinterB. C. M.et al (2025). Population pharmacokinetics of trimethoprim/sulfamethoxazole: dosage optimization for patients with renal insufficiency or receiving continuous renal replacement therapy. Clin. Pharmacol. and Ther.117 (1), 184–192. 10.1002/cpt.3421
62
LeonardM.RyanM. P.WatsonA. J.SchramekH.HealyE. (1999). Role of MAP kinase pathways in mediating IL-6 production in human primary mesangial and proximal tubular cells. Kidney International56 (4), 1366–1377. 10.1046/j.1523-1755.1999.00664.x
63
LiaoY.SmythG. K.ShiW. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinforma.30 (7), 923–930. 10.1093/bioinformatics/btt656
64
LipschutzJ. H.LiS.AriscoA.BalkovetzD. F. (2005). Extracellular signal-regulated kinases 1/2 control claudin-2 expression in Madin-darby canine kidney strain I and II cells. J. Biol. Chem.280 (5), 3780–3788. 10.1074/jbc.M408122200
65
LiuT.ZhangL.JooD.SunS. C. (2017). NF-κB signaling in inflammation. Signal Transduct. Target. Ther.2 (1), 1–9. 10.1038/sigtrans.2017.23
66
LiuA.ZengS.LuX.XiongQ.XueY.TongL.et al (2019). Overexpression of G2 and S phase-expressed-1 contributes to cell proliferation, migration, and invasion via regulating p53/FoxM1/CCNB1 pathway and predicts poor prognosis in bladder cancer. Int. J. Biol. Macromol.123, 322–334. 10.1016/j.ijbiomac.2018.11.032
67
LoveM. I.HuberW.AndersS. (2014). Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. Genome Biology15 (12), 550. 10.1186/s13059-014-0550-8
68
MacLeanA. (2001). Urinary tract infection in pregnancy. Int. J. Antimicrob. Agents17 (4), 273–277. 10.1016/s0924-8579(00)00354-x
69
MarzioniD.BanitaM.FeliciA.ParadinasF. J.NewlandsE.De NictolisM.et al (2001). Expression of ZO-1 and occludin in normal human placenta and in hydatidiform moles. Mol. Human Reproduction7 (3), 279–285. 10.1093/molehr/7.3.279
70
Matuszkiewicz-RowińskaJ.MałyszkoJ.WieliczkoM. (2015). State of the art paper urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. Archives Med. Sci.11 (1), 67–77. 10.5114/aoms.2013.39202
71
MirandaJ.Martín-TapiaD.Valdespino-VázquezY.AlarcónL.Espejel-NuñezA.Guzmán-HuertaM.et al (2019). Syncytiotrophoblast of placentae from women with zika virus infection has altered tight junction protein expression and increased paracellular permeability. Cells8 (10), 1174. 10.3390/cells8101174
72
MuandaF. T.SheehyO.BérardA. (2018). Use of trimethoprim–sulfamethoxazole during pregnancy and risk of spontaneous abortion: a nested case control study. Br. J. Clin. Pharmacol.84 (6), 1198–1205. 10.1111/bcp.13542
73
MuellerN. T.WhyattR.HoepnerL.OberfieldS.Dominguez-BelloM. G.WidenE. M.et al (2015). Prenatal exposure to antibiotics, cesarean section and risk of childhood obesity. Int. J. Obesity39 (4), 665–670. 10.1038/ijo.2014.180
74
MullinJ. M.LeathermanJ. M.ValenzanoM. C.HuertaE. R.VerrechioJ.SmithD. M.et al (2005). Ras mutation impairs epithelial barrier function to a wide range of nonelectrolytes. Mol. Biology Cell16 (12), 5538–5550. 10.1091/mbc.e05-04-0294
75
NadeauV. r.CharronJ. (2014). Essential role of the ERK/MAPK pathway in blood-placental barrier formation. Development141 (14), 2825–2837. 10.1242/dev.107409
76
NathansonS.MoreauE.Merlet-BenichouC.GilbertT. (2000). In utero and in vitro exposure to β-lactams impair kidney development in the rat. J. Am. Soc. Nephrol.11 (5), 874–884.
77
NguyenM. H.FornesR.KamauN.DanielssonH.CallensS.FranssonE.et al (2022). Antibiotic use during pregnancy and the risk of preterm birth: a population-based Swedish cohort study. J. Antimicrob. Chemother.77 (5), 1461–1467. 10.1093/jac/dkac053
78
OrganizationW. H. (2021). Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. World Health Organization.
79
OwaydhahW. H.AshtonN.VerreyF.GlazierJ. D. (2021). Differential expression of system L amino acid transporter subtypes in rat placenta and yolk sac. Placenta103, 188–198. 10.1016/j.placenta.2020.10.034
80
PanzerJ. J.RomeroR.GreenbergJ. M.WintersA. D.GalazJ.Gomez-LopezN.et al (2023). Is there a placental microbiota? A critical review and re-analysis of published placental microbiota datasets. BMC Microbiology23 (1), 76. 10.1186/s12866-023-02764-6
81
PidouxG.GerbaudP.GnidehouS.GrynbergM.GeneauG.GuibourdencheJ.et al (2010). ZO-1 is involved in trophoblastic cell differentiation in human placenta. Am. J. Physiol. Cell Physiol.298 (6), C1517–C1526. 10.1152/ajpcell.00484.2008
82
PoulsenM. S.RyttingE.MoseT.KnudsenL. E. (2009). Modeling placental transport: correlation of in vitro BeWo cell permeability and ex vivo human placental perfusion. Toxicol. Vitro23 (7), 1380–1386. 10.1016/j.tiv.2009.07.028
83
ProkopczykJ.RaczyńskiA.TroszyńskiM.WańkowiczB.WenzelE. (1979). Sulfamethoxazole concentration in the homogenate of the human embryo. Probl. Med. Wieku Rozw.9, 132–133.
84
RanY.FukuiH.XuX.WangX.EbisutaniN.TanakaY.et al (2020). Alteration of colonic mucosal permeability during antibiotic-induced dysbiosis. Int. J. Mol. Sci.21 (17), 6108. 10.3390/ijms21176108
85
ReelJ. R.TylR. W.LawtonA. D.LambJ. C. (1992). Reproductive toxicity of sulfamethazine in Swiss CD-1 mice during continuous breeding. Fundam. Appl. Toxicol.18 (4), 609–615. 10.1016/0272-0590(92)90121-w
86
RohartF.GautierB.SinghA.Lê CaoK. A. (2017). mixOmics: an R package for ‘omics feature selection and multiple data integration. PLoS Computational Biology13 (11), e1005752. 10.1371/journal.pcbi.1005752
87
RuanT.SunY.ZhangJ.SunJ.LiuW.PrinzR. A.et al (2022). H5N1 infection impairs the alveolar epithelial barrier through intercellular junction proteins via Itch-mediated proteasomal degradation. Commun. Biol.5 (1), 186. 10.1038/s42003-022-03131-3
88
RyanK. L.Dersch-MillsD.ClarkD. (2013). Trimethoprim–sulfamethoxazole for treatment of Stenotrophomonas maltophilia pneumonia in a neonate. Can. J. Hosp. Pharm.66 (6), 384–387. 10.4212/cjhp.v66i6.1305
89
SaberiA.SalarkiaE.SafiZ.SepehriG. (2017). Effects of subacute administration of co-trimoxazole and folic acid on ovarian tissue in adult female rats. Iran. J. Med. Sci.42 (6), 561–568.
90
SalariN.KhoshbakhtY.HemmatiM.KhodayariY.KhaleghiA.JafariF.et al (2023). Global prevalence of urinary tract infection in pregnant mothers: a systematic review and meta-analysis. Public Health224, 58–65. 10.1016/j.puhe.2023.08.016
91
SchulzeA. S.KleinauG.KrakowskyR.RochmannD.DasR.WorthC. L.et al (2022). Evolutionary analyses reveal immune cell receptor GPR84 as a conserved receptor for bacteria-derived molecules. Iscience25 (10), 105087. 10.1016/j.isci.2022.105087
92
Seyed ToutounchiN.HogenkampA.VarastehS.van’t LandB.GarssenJ.KraneveldA. D.et al (2019). Fusarium mycotoxins disrupt the barrier and induce IL-6 release in a human placental epithelium cell line. Toxins11 (11), 665. 10.3390/toxins11110665
93
ShinkaiM.FosterG. H.RubinB. K. (2006). Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am. J. Physiology-Lung Cell. Mol. Physiology290 (1), L75–L85. 10.1152/ajplung.00093.2005
94
SivalingamS. P.SimS. H.JasperL. C. W.WangD.LiuY.OoiE. E. (2008). Pre-and post-exposure prophylaxis of experimental burkholderia pseudomallei infection with doxycycline, amoxicillin/clavulanic acid and co-trimoxazole. J. Antimicrob. Chemother.61 (3), 674–678. 10.1093/jac/dkm527
95
SmilackJ. D. (1999). “Trimethoprim-sulfamethoxazoles,” in Mayo Clinic Proceedings (Elsevier).
96
ThompsonB. B.HolzerP. H.KlimanH. J. (2024). Placental pathology findings in unexplained pregnancy losses. Reprod. Sci.31 (2), 488–504. 10.1007/s43032-023-01344-3
97
TorryD. S.LeavenworthJ.ChangM.MaheshwariV.GroeschK.BallE. R.et al (2007). Angiogenesis in implantation. J. Assist. Reprod. Genet.24 (7), 303–315. 10.1007/s10815-007-9152-7
98
TossettaG.PaolinelliF.AvelliniC.SalvoliniE.CiarmelaP.LorenziT.et al (2014). IL-1β and TGF-β weaken the placental barrier through destruction of tight junctions: an in vivo and in vitro study. Placenta35 (7), 509–516. 10.1016/j.placenta.2014.03.016
99
TubitaA.PapiniD.TusaI.RovidaE. (2025). Dual-specificity protein phosphatases targeting extracellular signal-regulated kinases: friends or foes in the biology of cancer?Int. J. Mol. Sci.26 (17), 8342. 10.3390/ijms26178342
100
TulstrupM.V.-L.ChristensenE. G.CarvalhoV.LinningeC.AhrnéS.HøjbergO.et al (2015). Antibiotic treatment affects intestinal permeability and gut microbial composition in wistar rats dependent on antibiotic class. PloS One10 (12), e0144854. 10.1371/journal.pone.0144854
101
UeharaI.KimuraT.TanigakiS.FukutomiT.SakaiK.ShinoharaY.et al (2014). Paracellular route is the major urate transport pathway across the blood‐placental barrier. Physiol. Rep.2 (5), e12013. 10.14814/phy2.12013
102
UmapathyA.ClarkA.SehgalA.KaranamV.RajaramanG.KalionisB.et al (2024). Molecular regulators of defective placental and cardiovascular development in fetal growth restriction. Clin. Sci.138 (13), 761–775. 10.1042/cs20220428
103
UrnessL. D.LiC.WangX.MansourS. L. (2008). Expression of ERK signaling inhibitors Dusp6, Dusp7, and Dusp9 during mouse ear development. Dev. Dyn.237 (1), 163–169. 10.1002/dvdy.21380
104
U.S. Food and Drug Administration (2021). Bactrim (Sulfamethoxazole and Trimethoprim) Tablets Label. U.S. Food and Drug Administration.
105
van HoveH.MathiesenL.FreriksenJ.VähäkangasK.ColbersA.BrownbillP.et al (2022). Placental transfer and vascular effects of pharmaceutical drugs in the human placenta ex vivo: a review. Placenta122, 29–45. 10.1016/j.placenta.2022.03.128
106
VenkataramanC.KuoF. (2005). The G-protein coupled receptor, GPR84 regulates IL-4 production by T lymphocytes in response to CD3 crosslinking. Immunol. Letters101 (2), 144–153. 10.1016/j.imlet.2005.05.010
107
VilotićA.Nacka-AleksićM.PirkovićA.Bojić-TrbojevićŽ.DekanskiD.Jovanović KrivokućaM. (2022). IL-6 and IL-8: an overview of their roles in healthy and pathological pregnancies. Int. J. Mole. Sci.23 (23), 14574. 10.3390/ijms232314574
108
WalterJ.MwiyaM.ScottN.KasondeP.SinkalaM.KankasaC.et al (2006). Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-Infected women with low CD4 cell counts. J. Infectious Diseases194 (11), 1510–1518. 10.1086/508996
109
WaltzerW. C. (1981). The urinary tract in pregnancy. J. Urology125 (3), 271–276. 10.1016/s0022-5347(17)55008-9
110
WangJ.ShaoW.NiuH.YangT.WangY.CaiY. (2019). Immunomodulatory effects of colistin on macrophages in rats by activating the p38/MAPK pathway. Front. Pharmacol.10, 729. 10.3389/fphar.2019.00729
111
WeilerH. (2005). Vascular biology of the placenta. in Endothelial Cells in Health and Disease.Editor W.C. Aird (Taylor & Francis), 289–313. 10.3109/9780203025956-20
112
WinterhagerE.GellhausA. (2017). Transplacental nutrient transport mechanisms of intrauterine growth restriction in rodent models and humans. Front. Physiology8, 951. 10.3389/fphys.2017.00951
113
World Health Organization (2014). Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-Related infections among adults, adolescents and children: recommendations for a public health approach: december 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection.
114
WuT.HuE.XuS.ChenM.GuoP.DaiZ.et al (2021). clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation2 (3), 100141. 10.1016/j.xinn.2021.100141
115
WuS.WangJ.GuoQ.LanH.SunY.RenM.et al (2023). Prevalence of human immunodeficiency virus, syphilis, and hepatitis B and C virus infections in pregnant women: a systematic review and meta-analysis. Clin. Microbiology Infection29 (8), 1000–1007. 10.1016/j.cmi.2023.03.002
116
WuH.LiY.LiX.HuangW.HuangZ.LaiX.et al (2024). IL-17A disrupts the nasal mucosal epithelial barrier in patients with chronic rhinosinusitis by activating the ERK/STAT3 pathway. Rhinology62 (6), 726–738. 10.4193/Rhin24.127
117
XieC.XiangW.ShenH.ShenJ. (2021). GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma. J. Orthop. Surg. Res.16, 1–11. 10.1186/s13018-021-02859-8
118
ZhouH.ZhaoC.WangP.YangW.ZhuH.ZhangS. (2023). Regulators involved in trophoblast syncytialization in the placenta of intrauterine growth restriction. Front. Endocrinol.14, 1107182. 10.3389/fendo.2023.1107182
119
ZhouX.ZhaoX.DongH.GaoY. (2024). Chrysene contribution to bronchial asthma: activation of TRPA1 disrupts bronchial epithelial barrier via ERK pathway. Ecotoxicol. Environ. Saf.286, 117095. 10.1016/j.ecoenv.2024.117095
120
ZourbasS.DubanchetS.MartalJ.ChaouatG. (2001). Localization of pro-inflammatory (IL-12, IL-15) and anti-inflammatory (IL-11, IL-13) cytokines at the foetomaternal interface during murine pregnancy. Clin. and Exp. Immunol.126 (3), 519–528. 10.1046/j.1365-2249.2001.01607.x
Summary
Keywords
antibiotic, cell-cell junction, co-trimoxazole, DUSP, MAPK, placenta, pregnancy
Citation
Azarmi M, Saei H, van Vugt IAC, Thijssen S, van ’t Land B, van Elburg R, Garssen J, Folkerts G, Hogenkamp A and Braber S (2026) Co-trimoxazole-induced reproductive toxicity and placental-barrier disruption: impact on cell-cell junctions and ERK signaling pathway . Front. Cell Dev. Biol. 14:1800328. doi: 10.3389/fcell.2026.1800328
Received
30 January 2026
Revised
19 April 2026
Accepted
06 May 2026
Published
08 June 2026
Volume
14 - 2026
Edited by
Zhenshan Yang, Hubei University of Medicine, China
Reviewed by
Kyung Min Jung, University of Missouri, United States
Shahrokh Paktinat, University of Washington, United States
Updates
Copyright
© 2026 Azarmi, Saei, van Vugt, Thijssen, van ’t Land, van Elburg, Garssen, Folkerts, Hogenkamp and Braber.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Saskia Braber, s.braber@uu.nl
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.